DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Response to desipramine treatment in adolescent major depression.

Author(s): Boulos C, Kutcher S, Marton P, Simeon J, Ferguson B, Roberts N

Affiliation(s): Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada.

Publication date & source: 1991, Psychopharmacol Bull., 27(1):59-65.

Publication type: Clinical Trial; Controlled Clinical Trial; Randomized Controlled Trial

Thirty adolescents (ages 15-20) who met DSM-III-R criteria for major depressive disorder completed a double-blind, placebo-controlled, 6-week, fixed-dose (200 mg daily) study of desipramine (DMI). Thirty-three percent of the placebo group and 50 percent of the DMI group improved (greater than or equal to 50% change on the Hamilton Rating Scale for Depression). Subjective reports of adverse effects did not significantly differentiate the two groups. Major adverse effects, necessitating study discontinuation, occurred solely in the DMI group.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017